Cart
×
The clinical impact of the FORCE™ platform:
Duchenne muscular dystrophy (DMD) – An update on the DELIVER trial of DYNE-251 in males with DMD mutations amenable to exon 51 skipping.
PRESENTED BY:
Ashish Dugar, Ph.D., MBA
Chief Medical Affairs Officer
April 1, 2025 | 9 AM Pacific | 12 PM Eastern
REGISTER HERE